Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: Exp Hematol. 2009 May;37(5):533–538. doi: 10.1016/j.exphem.2009.02.001

Figure 3.

Figure 3

The effect of A2bAR antagonist, MRS1754, on TNF-α release from macrophages treated with BAY 60-6583. (A) TNF-α released from WT macrophages pre-incubated with MRS1754 (10 μM) and incubated with BAY 60-6583 (1 μM) and followed by LPS (10 μg/ml) challenge as indicated under Methods. TNF-α released is shown as a ratio to the maximal TNF-α level in vehicle-treated cells (designated as 1). Shown are averages +/- SD (n=3). (B) TNF-α released from A2bAR KO peritoneal macrophages treated as in (A). Shown are averages +/- SD (n=3). *, p < 0.05 for vehicle-treated cells as compared to BAY 60-6583-treated cells, and BAY 60-6583-treated cells as compared to BAY 60-6583 plus MRS1754-treated cells or just MRS1754-treated cells.